Bacterial Outer Membrane Vesicles Could Transform Vaccine Formulations
Engineered Bacterial OMV. Credit: Kendrick B. Turner and Scott A. Walper, Bentham Science Publishers
Outer membrane vesicles, biological nanoparticles shed during normal growth by bacteria, have seen significant recent advances in engineering and are thus finding new utility as therapeutic and drug delivery agents. One specific research focus explored recently in the literature is the use of bacterial vesicles as adjuvants in vaccine formulations. Early success in this area has demonstrated protection against infection by a number of bacterial species in animal models by engineering vesicles to display species-specific antigens as cargo, either within the interior of the vesicles or displayed on the exterior vesicle surface.
In an effort to highlight recent advances in this field, this article explores recent and ongoing efforts to develop novel engineering methods aimed at providing new functionalities for bacterial vesicles as they apply to vaccine formulations. Specifically, emerging technologies for engineering these structures, including cargo loading and surface modification will be explored.
Bacterial vesicles show great promise as biologically-derived nanoparticles that could function as a platform technology in a variety of fields. With continued development of novel engineering tools, and an increased understanding in their biogenesis and biological fate in living systems there is significant potential to develop bacterial vesicles as tools for not only vaccine development but also for use in the delivery of therapeutic compounds to targeted cells.
This article has been republished from materials provided by Bentham Science. Note: material may have been edited for length and content. For further information, please contact the cited source.
Turner, K. B., & Walper, S. A. (2017). Bacterial Outer Membrane Vesicles: An Emerging Tool in Vaccine Development, as Adjuvants, and for Therapeutic Delivery. Drug Delivery Letters, 07. doi:10.2174/2210303107666170725163826
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE